References:
1. Deshpande, A., Mailis-Gagnon, A., Zoheiry, N., & Lakha, S. F. (2015). Efficacy and adverse effects of medical marijuana for chronic noncancer pain. Canadian Family Physician, 61(8), e372-81.
2. Piomelli, D., & Russo, E. B. (2016). The Cannabis sativa Versus Cannabis indica Debate: An Interview with Ethan Russo, MD. Cannabis and cannabinoid research, 1(1), 44–46. doi:10.1089/can.2015.29003.ebr
3. Turcotte, C., Blanchet, M.C., Laviolette, M., and Flamand, N. (2016). The CB2 receptor and its role as a regulator of inflammation. Cellular and molecular life sciences : CMLS, 73(23), 4449–4470. doi: 10.1007/s00018-016-2300-4.
4. Linge, R., Jiménez-Sánchez, L., Campa, L., Pilar-Cuéllar, F., Vidal, R., Pazos, A., Adell, A., and Díaz, Á. (2016). Cannabidiol induces rapid-acting antidepressant-like effects and enhances cortical 5-HT/glutamate neurotransmission: role of 5-HT1A receptors. Neuropharmacology,71, 56-67.
5. Murillo-Rodríguez, E., Sarro-Ramirez, A., Sanchez, D., Mijangos-Moreno, S., Tejeda-Padron, A., Poot-Ake, A., Guzman, K., Pacheco-Pantoja, E., and Arias-Carrion, O. (2014). Potential effects of cannabidiol as a wake-promoting agent. Current neuropharmacology, 12(3), 269–272. doi:10.2174/1570159X11666131204235805.